Clinical Role - Payer

Skidki-na-vse® is a leader in providing the latest clinical updates, patient counseling tools and innovative solutions to payers, pharmacy benefit managers, formulary chairs and directors, managed care directors, quality assurance directors, and Medicaid/Medicare directors.

Cancer Drug Costs May Not Be Factored Into Reimbursement
Study finds health-related quality of life is often not collected for novel cancer drugs when they are submitted for reimbursement.
Study: Number of Drug
A new study by Prime Therapeutics LLC has shown a sharp increase in the number of drug "super spenders," defined by the researchers as members with pharmacy and medical drug therapy claims of $250,000 or more annually.
More Than Just a Number: Assessing The Value of Innovative Treatments
Value assessment frameworks are expected to play a more pivotal role in decisions that affect future patient choice and access.
Out-of-Pocket Costs Grew 7-Fold for Medicare Beneficiaries with Multiple Sclerosis
Rising drug prices for disease-modifying therapies resulted in substantial increases in spending for Medicare beneficiaries with multiple sclerosis.
Importation Plan Aims to Lower US Prescription Drug Prices Amid Safety Concerns
Announced by the HHS and FDA, the plan seeks to safely import medications that would provide a cost savings to consumers, but some pharmacy and other health care professionals have expressed concerns. 
Specialty Drugs Remain a Costly Concern for Employers With No Easy Answers
Costs remain the top concern of healthcare purchasers of pharmacy benefits, but employers are also concerned with ensuring appropriate use of medication and adherence to medication, according to a new report from the Pharmacy Benefit Management Institute (PBMI).
Is There an Alternative to PBM Rebates? ICER Paper Examines 3 Options
With discussion and debate happening for months in Washington, DC, over drug pricing and the role of pharmacy benefit managers (PBMs), the Institute
for Clinical and Economic Review (ICER) published a white paper this week that analyzes 3 possible alternatives to the pharmaceutical rebate system fostered by PBMs.
Current and Future Status of Drug Pricing Reform as the Blueprint Approaches the 1-Year Mark
Several efforts are underway nearly a year after the Trump administration released its blueprint to lower drug prices in May 2018, but tracking their outcomes depends on what metric is used to define drug prices, according to a session at the Academy of Managed Care Pharmacy Managed Care & Specialty Pharmacy Annual Meeting, held March 25-28 in San Diego, California.
Rule Eliminating Rebates Leaves Plenty of Uncertainty
A policy from the Trump administration to benefit patients and alleviate the high cost of prescription drugs would eliminate rebates from pharmaceutical
companies to pharmacy benefit managers.
Prescription Benefits Consultant Sees Opportunities for Employers in Debate Over Rebates
Prescription benefits consultant Chris Robbins, chief executive of cer of Arxcel, describes the finger-pointing in Congress over lowering drug costs this way: “If it weren’t so true, it might be almost humorous.”
Cigna, Express Scripts Capping Insulin Co-Pays at $25 for Participating Commercial Members
A day after stakeholders told a House of Representatives subcommittee about problems accessing and paying for insulin, Cigna and its pharmacy benefit manager Express Scripts said they are launching a program for patients with diabetes in their commercial plans so that they pay no more than $25 for a 30-day supply of insulin.
Connecticut Legislation Supports Drug Pricing Transparency
A new legislation signed by Governor Ned Lamont has brought cause for celebration among Connecticut pharmacists and patients alike in the fight for drug pricing transparency.
+ Load More